Article
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2008
Wong Alvin S, Soong Richie, Seah Serena Bee-Kee, Lim Siew-Woon, Chuah Khoon-Leong, Nga Min-En, Chin Tan-Min, Soo Ross A
Abstract excerpt
INTRODUCTION: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are gaining an increasing role in the management of advanced non-small cell lung cancer (NSCLC). There is mounting interest in the benefit of administering a second TKI after failur...
Topics
- Adult
- Aged
- Carcinoma, Non-Small-Cell Lung
- Disease Progression
- ErbB Receptors
- Erlotinib Hydrochloride
- Female
- Gefitinib
- Humans
- Lung Neoplasms
- Lymphatic Metastasis
- Male
- Middle Aged
- Mutation